NASDAQ / LIVE COMPANY INTELLIGENCE

Eupraxia Pharmaceuticals Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKEREPRX
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / EPRX COVERAGE

What’s moving Eupraxia Pharmaceuticals Inc. now

Current reporting with the operating signal separated from the noise.

01
Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders

Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders

Investors are testing whether Eupraxia Pharmaceuticals Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
02
Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer

Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer

The story matters when it changes Eupraxia Pharmaceuticals Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
Eupraxia Pharmaceuticals Inc. (EPRX) Upgraded to Buy: Here's Why

Eupraxia Pharmaceuticals Inc. (EPRX) Upgraded to Buy: Here's Why

The story matters when it changes Eupraxia Pharmaceuticals Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
04
Eupraxia Pharmaceuticals Inc. to Present at Multiple Upcoming Investor and Scientific Conferences in April and May 2025

Eupraxia Pharmaceuticals Inc. to Present at Multiple Upcoming Investor and Scientific Conferences in April and May 2025

The story matters when it changes Eupraxia Pharmaceuticals Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
05
Eupraxia Pharmaceuticals Inc. Announces Appointment of Bruce Cousins as President & CFO

Eupraxia Pharmaceuticals Inc. Announces Appointment of Bruce Cousins as President & CFO

The story matters when it changes Eupraxia Pharmaceuticals Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
06
EUPRAXIA PHARMS INC by EUPRAXIA PHARMACEUTICALS INC Stock (OTC:EPRXF), Short Interest Report

EUPRAXIA PHARMS INC by EUPRAXIA PHARMACEUTICALS INC Stock (OTC:EPRXF), Short Interest Report

Investors are testing whether Eupraxia Pharmaceuticals Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
PRIMARY DOCUMENTS / SEC EDGAR

Latest EPRX filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

6-KOfficial SEC filingFiled 2026-07-15 · Period 2026-07-15SEC ↗6-KOfficial SEC filingFiled 2026-07-13 · Period 2026-07-13SEC ↗6-KOfficial SEC filingFiled 2026-07-07 · Period 2026-07-07SEC ↗6-KOfficial SEC filingFiled 2026-06-22 · Period 2026-06-19SEC ↗6-KOfficial SEC filingFiled 2026-05-29 · Period 2026-06-18SEC ↗6-KOfficial SEC filingFiled 2026-05-29 · Period 2026-05-28SEC ↗6-KOfficial SEC filingFiled 2026-05-28 · Period 2026-05-28SEC ↗SCHEDULE 13G/AOfficial SEC filingFiled 2026-05-12SEC ↗
EARNINGS / QUARTERLY TRACKER

Eupraxia Pharmaceuticals Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.